首页分子通(S)-3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one trifluoroacetic acid salt
(S)-3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one trifluoroacetic acid salt
(S)-3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one trifluoroacetic acid salt
Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)
摘要:
Optimization of a 5-oxopyrrolopyridine series based upon structure activity relationships (SARs) developed from our previous efforts on a number of related bicyclic series yielded compound 2s (BMS-767778) with an overall activity, selectivity, efficacy, PK, and developability profile suitable for progression into the clinic. SAR in the series and characterization of 2s are described.